NanoTemper Technologies

NanoTemper’s mission is to enable everyone to do science that matters by always pushing the limits

Stefan Duhr and Philipp Baaske set out to build a company to address challenges researchers were facing with the ultimate goal of helping to move science forward.

NanoTemper was started in 2008 after Stefan and Philipp met at Ludwig-Maximilians-University Munich. At the time, the effect of thermophoresis was not known within the Life Sciences community, but Stefan and Philipp knew that it was important. Realizing the shortcomings of current protein research techniques, they came up with a method, MicroScale Thermophoresis that was enormously sensitive, and would bring researchers one step closer to developing better drugs faster.

ebook: The researcher’s guide to measuring binding affinity

ebook: The definitive guide to understanding protein stability

ebook: How FBDD improves hit rates & delivers high-value targets

Guide: Five ways biophysical tools help brain studies

ebook: How to start your own lab

Application note: Faster and more reliable quantification of oligonucleotide interaction with human serum albumin using MST

Determining the structure of nanobodies using nuclear magnetic resonance spectroscopy

An IgM antibody platform to tackle SARS-CoV-2 and its variants

Bispecific antibodies: the next generation of immuno-oncology drugs

Oncology meets immunology – antibody-mediated regulation of the immune response

Antibody therapeutics for COVID-19

Defusing antibody neutralisers in AAV gene therapy

Expert view: Increasing the efficiency of biologics development: the secret is precise and reliable stability characterisation of candidate molecules

Antibodies In-Depth Focus 2020

Upstream Bioprocessing In-Depth Focus 2019

Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application

Expert view: Tackling drug discovery inefficiencies requires diverse libraries, technologies with broader applicability and actionable insights

Improved screening of therapeutic candidates using integrated fragment-based approaches

Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application